93534-22-6

Usage

Uses

Used in Pharmaceutical Synthesis:
Ethanone, 1-(3,4-dichlorophenyl)-2-phenylis employed as a key intermediate in the production of pharmaceuticals. Its unique structure allows for the creation of a variety of medicinal compounds, contributing to the development of new drugs and therapies.
Used in Organic Compound Synthesis:
This chemical compound serves as an essential building block in the synthesis of other organic compounds. Its versatility in chemical reactions makes it a valuable asset in the field of organic chemistry, facilitating the production of a range of products.
Used in Research and Chemical Manufacturing:
Ethanone, 1-(3,4-dichlorophenyl)-2-phenylis utilized in research settings to explore its properties and potential applications. Additionally, it plays a role in chemical manufacturing processes, where its reactivity and stability are harnessed to produce a multitude of chemical products.
Used in Chemical Intermediates Industry:
As a chemical intermediate, Ethanone, 1-(3,4-dichlorophenyl)-2-phenylis used in the Chemical Intermediates Industry to facilitate the production of a wide array of end products. Its presence in this industry underscores its importance in the synthesis of various compounds that find applications in different sectors.

Upstream product

• 103-82-2 phenylacetic acid 
• 2905-68-2 methyl 3,4-dichlorobenzoate 
• 100-39-0 benzyl bromide 
• 95392-03-3 2-(3,4-dichlorophenyl)-2-((trimethylsilyl)oxy)acetonitrile 
• 6287-38-3 3,4-dichlorobenzaldehyde 
• 4039-32-1 lithium hexamethyldisilazane 
• 151169-75-4 3,4-dichlophenylboronic acid 
• 103-80-0 phenylacetyl chloride 

Downstream Products

• 1283117-56-5 6-(3,4-dichlorophenyl)-4-(3-ethoxy-4-hydroxy-5-nitrophenyl)-5-phenyl-3,4-dihydropyrimidin-2(1H)-one 
• 191014-79-6 3-phenyl-4-(3',4'-dichlorophenyl)-4-oxo-2-butenoic acid 

Relevant academic research and scientific papers

Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics

The retinoid X receptors (RXR) are ligand-activated transcription factors involved in multiple regulatory networks as universal heterodimer partners for nuclear receptors. Despite their high therapeutic potential in many pathologies, targeting of RXR has only been exploited in cancer treatment as the currently available RXR agonists suffer from exceptional lipophilicity, poor pharmacokinetics (PK), and adverse effects. Aiming to overcome the limitations and to provide improved RXR ligands, we developed a new potent RXR ligand chemotype based on the nonsteroidal anti-inflammatory drug oxaprozin. Systematic structure-activity relationship analysis enabled structural optimization toward low nanomolar potency similar to the well-established rexinoids. Cocrystal structures of the most active derivatives demonstrated orthosteric binding, and in vivo profiling revealed superior PK properties compared to current RXR agonists. The optimized compounds were highly selective for RXR activation and induced RXR-regulated gene expression in native cellular and in vivo settings suggesting them as excellent chemical tools to further explore the therapeutic potential of RXR.

Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain

The emerging pharmacological target soluble epoxide hydrolase (sEH) is a bifunctional enzyme exhibiting two different catalytic activities that are located in two distinct domains. Although the physiological role of the C-terminal hydrolase domain is well-investigated, little is known about its phosphatase activity, located in the N-terminal phosphatase domain of sEH (sEH-P). Herein we report the discovery and optimization of the first inhibitor of human and rat sEH-P that is applicable in vivo. X-ray structure analysis of the sEH phosphatase domain complexed with an inhibitor provides insights in the molecular basis of small-molecule sEH-P inhibition and helps to rationalize the structure-activity relationships. 4-(4-(3,4-Dichlorophenyl)-5-phenyloxazol-2-yl)butanoic acid (22b, SWE101) has an excellent pharmacokinetic and pharmacodynamic profile in rats and enables the investigation of the physiological and pathophysiological role of sEH-P in vivo.

NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain

Herein we report the synthesis and evaluation of a series of thiosemicarbazones as potential inhibitors of cysteine proteases relevant to parasitic diseases. Derivatives of thiosemicarbazone 1 were discovered to be potent inhibitors of cruzain and rhodesain, crucial proteases in the life cycles of Trypanosoma cruzi and T. brucei rhodesiense, the organisms causing Chagas' disease and sleeping sickness. However, the entire series had only modest potency against falcipain-2, an essential protease for Plasmodium falciparum, the organism causing malaria. Among the active inhibitors, several potently inhibited proliferation of cultures of T. brucei. However, only modest activity was observed in inhibition of proliferation of T. cruzi or P. falciparum. Herein we report the synthesis and evaluation of a series of thiosemicarbazones as potential inhibitors of cysteine proteases relevant to parasitic diseases. Derivatives of thiosemicarbazone 1 were discovered to be potent inhibitors of cruzain and rhodesain, crucial proteases in the life cycles of Trypanosoma cruzi and T. brucei rhodesiense, the organisms causing Chagas' disease and sleeping sickness. However, the entire series had only modest potency against falcipain-2, an essential protease for Plasmodium falciparum, the organism causing malaria. Among the active inhibitors, several potently inhibited proliferation of cultures of T. brucei. However, only modest activity was observed in inhibition of proliferation of T. cruzi or P. falciparum.

Isoxazole compounds as cyclooxygenase inhibitors

A class of substituted isoxazolyl compounds is described for use in treating cyclooxygenase-2 related disorders. Compounds of particular interest are defined by Formula I STR1 wherein R1, R2, and R3, are described in the specification.

N-aryl-3-aryl-4,5-dihydro-1H-pyrazole-1-carboxamides and methods of their production

This invention relates to novel N-aryl-3-aryl-4,5-dihydro-1H-pyrazole-1-carboxamide compounds which are useful as pesticides, compositions containing those compounds, methods of controlling pests and processes for preparing these compounds.

Insecticidal n-aryl-3-aryl-4,5-dihydro-1h-pyrazole-1-carboxamides

This invention relates to N-aryl-3-aryl-4,5-dihydro-1H-pyrazole-1-carboxamide compounds which are useful as pesticides, compositions containing those compounds, methods of controlling pests and processes for preparing these compounds.